Table 1.
Clinical characteristicsa
| PT | Age | Sex | 1p19q deletion | Comment | Path | % Mib-1 | Loc | SX | Recc | C+ | Pminost-op XRT | TTP (mos) | Alive (Y/N) | Length F/U (mos) | Status at last F/U |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1D | 47 | F | + | 19q-relative deletion | O–II | 0.2 | R-Fr | SZ | N | NO | STR | none | Y | 45 | S |
| 2D | 48 | M | + | O–II | 1.2 | L-Fr | SZ | N | YESc | GTR | none | Y | 56 | S | |
| 3D | 37 | M | + | O–II | 0.9 | R-Fr | SZ | N | NO | GTR | none | Y | 45 | S | |
| 4D | 29 | F | + | O–II | 0 | L-Fr | SZ | N | YESc | GTR | none | Y | 67 | S | |
| 5D | 29 | M | + | O–II | 0.5 | R-Fr | P | Y | NO | GTR | none | Y | 34 | P | |
| 1UD | 65 | M | − | O–II | 0 | L-T | SZ | N | NO | GTR | LTF/U | NA | NA | NA | |
| 2UD | 34 | M | − | 19 polysomy | O–II | NA | R-Fr | HA | N | NO | GTR | LTF/U | NA | NA | NA |
| 3UD | 46 | F | − | 19qpolysomy | O–II | 1 | L-Fr | SZ | N | NO | STR | none | Y | 29 | S |
| 4UD | 34 | M | − | O–II | 0b | R-Fr | SZ | N | NO | STR | 7 | Y | 9 | P | |
| 5UD | 28 | F | − | 1, 19polysomy | O–II | 0.3 | L-Fr | SZ | N | NO | STR | none | |||
a
A: alive, C+: contrast enhancement, CTX: chemotherapy, D: deleted, EOR: extent of resection, Fr: frontal, FU: follow up, GTR: Gross total resection, HA: headache, LT F/U: lost to follow-up, NA: no data, OII: oligodendroglioma grade II, P: progression, path: pathology, recc: recurrence, S: stable, STR: subtotal resection, surv: survival, SX: symptoms, SZ: seizure, T: temporal, TTP: time to progression, UD: undeleted, XRT: irradiation.
b
Focal Mib-1 25%.
c
Minimal.